| Dr Robert Daniel Claflin, DO | |
|
840 E Mckellips Rd Bldg 2, Mesa, AZ 85203 | |
| (602) 491-0703 | |
| Not Available |
| Full Name | Dr Robert Daniel Claflin |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 7 Years |
| Location | 840 E Mckellips Rd Bldg 2, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164959441 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthyu Family Medicine Llc | 6204224918 | 18 |
News Archive
Dialysis treatments do not affect the heart health of kidney disease patients who have had a heart attack, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Since cardiovascular disease is the most common cause of death in kidney disease patients, the findings are good news for individuals who need the treatments.
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
For Immediate Release -Scripps Research Institute scientists have been awarded approximately $65 million in four five-year grants as part of the National Institutes of Health's (NIH) latest round of structural biology funding. The projects will focus on determining the shapes and functions of proteins and protein complexes that are important in biology and medicine.
CQ HealthBeat reports that some Republican state executives were not impressed with the decision by Centers for Medicare & Medicaid Services officials to allow states that proceed with expansion plans now to scale back their Medicaid programs later.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
› Verified 4 days ago
| Entity Name | Integrated Medical Management, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598266710 PECOS PAC ID: 4789947003 Enrollment ID: O20180418001719 |
News Archive
Dialysis treatments do not affect the heart health of kidney disease patients who have had a heart attack, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Since cardiovascular disease is the most common cause of death in kidney disease patients, the findings are good news for individuals who need the treatments.
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
For Immediate Release -Scripps Research Institute scientists have been awarded approximately $65 million in four five-year grants as part of the National Institutes of Health's (NIH) latest round of structural biology funding. The projects will focus on determining the shapes and functions of proteins and protein complexes that are important in biology and medicine.
CQ HealthBeat reports that some Republican state executives were not impressed with the decision by Centers for Medicare & Medicaid Services officials to allow states that proceed with expansion plans now to scale back their Medicaid programs later.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
› Verified 4 days ago
| Entity Name | Healthyu Family Medicine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669149787 PECOS PAC ID: 6204224918 Enrollment ID: O20211029001834 |
News Archive
Dialysis treatments do not affect the heart health of kidney disease patients who have had a heart attack, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Since cardiovascular disease is the most common cause of death in kidney disease patients, the findings are good news for individuals who need the treatments.
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
For Immediate Release -Scripps Research Institute scientists have been awarded approximately $65 million in four five-year grants as part of the National Institutes of Health's (NIH) latest round of structural biology funding. The projects will focus on determining the shapes and functions of proteins and protein complexes that are important in biology and medicine.
CQ HealthBeat reports that some Republican state executives were not impressed with the decision by Centers for Medicare & Medicaid Services officials to allow states that proceed with expansion plans now to scale back their Medicaid programs later.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Daniel Claflin, DO 840 E Mckellips Rd Bldg 2, Mesa, AZ 85203-9645 Ph: (602) 491-0703 | Dr Robert Daniel Claflin, DO 840 E Mckellips Rd Bldg 2, Mesa, AZ 85203 Ph: (602) 491-0703 |
News Archive
Dialysis treatments do not affect the heart health of kidney disease patients who have had a heart attack, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Since cardiovascular disease is the most common cause of death in kidney disease patients, the findings are good news for individuals who need the treatments.
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
For Immediate Release -Scripps Research Institute scientists have been awarded approximately $65 million in four five-year grants as part of the National Institutes of Health's (NIH) latest round of structural biology funding. The projects will focus on determining the shapes and functions of proteins and protein complexes that are important in biology and medicine.
CQ HealthBeat reports that some Republican state executives were not impressed with the decision by Centers for Medicare & Medicaid Services officials to allow states that proceed with expansion plans now to scale back their Medicaid programs later.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
› Verified 4 days ago
Dr. Jose Rapanan Jr., DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10032 E Southern Ave, Mesa, AZ 85209 Phone: 480-351-2850 | |
Jennifer Christine Fendler, NP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 924 N Country Club Dr, Mesa, AZ 85201 Phone: 480-601-3528 | |
George Ting, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1111 N Stapley Dr, Mesa, AZ 85203 Phone: 480-464-8500 | |
Dr. Thomas P Porter, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1950 S Country Club Dr, Mesa, AZ 85210 Phone: 480-969-1446 Fax: 480-969-9105 | |
Dana S Farris, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10238 E Hampton Ave Ste 506, Mesa, AZ 85209 Phone: 480-834-7546 Fax: 480-833-8313 | |
Nancy Mucha, CNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2843 N 89th St, Mesa, AZ 85207 Phone: 480-396-3482 | |
Ryan Elisabeth Romo, Family Medicine Medicare: Medicare Enrolled Practice Location: 1705 W Main St, Mesa, AZ 85201 Phone: 877-809-5092 |